Integra LifeSciences Holdings Corporation (IART) Cash Flow Statement
Where IART’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- $50.4M −61.1% vs 2024
- Capital expenditures
- $95.6M 5.8% of revenue
- Free cash flow
- −$45.3M −2.8% margin
- Returned to shareholders
- $221,000
- Change in cash
- −$11.3M cash at year-end $235.0M
Drawn to scale: where the cash came from and how it was used. Hover for values.
IART operating cash flow, capex and free cash flow
IART cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | $116.4M2016 | $50.4M2025 | −8.9%/yr | |
| Capital expenditures | $47.3M2016 | $95.6M2025 | +8.1%/yr | |
| Free cash flow | $69.1M2016 | −$45.3M2025 | — | |
| Free cash flow margin | 7.0%2016 | −2.8%2025 | −9.7 pts | |
| Operating cash flow / net income | 1.562016 | 2.072023 | +0.50 | |
| Stock-based compensation | $17.3M2016 | $18.6M2025 | +0.8%/yr | |
| Dividends paid | $02016 | $93.2M2023 | — | |
| Share buybacks (net) | $4.9M2016 | $221,0002025 | −29.1%/yr | |
| Capex / revenue | 4.8%2016 | 5.8%2025 | +1.1 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
IART cash flow by activity
IART net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
IART cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$516.5M | −$6.9M | $67.7M | $180.6M | $169.1M | $133.9M | $50.2M | $60.8M | $64.7M | $74.6M |
| Depreciation & amortization | $151.8M | $140.9M | $123.5M | $118.3M | $119.8M | $116.0M | $109.5M | $110.7M | $88.9M | $72.7M |
| Stock-based compensation | $18.6M | $24.4M | $20.1M | $27.7M | $36.2M | $19.6M | $21.3M | $20.8M | $21.6M | $17.3M |
| Change in working capital | −$33.7M | −$31.0M | −$81.6M | −$39.4M | $18.2M | −$41.3M | −$14.5M | $1.7M | −$1.3M | −$11.2M |
| Other non-cash items | $430.2M | $2.1M | $10.1M | −$22.7M | −$30.9M | −$24.4M | $65.0M | $5.6M | −$59.4M | −$36.9M |
| Cash from operating activities | $50.4M | $129.4M | $140.0M | $264.5M | $312.4M | $203.8M | $231.4M | $199.7M | $114.5M | $116.4M |
| Investing activities | ||||||||||
| Capital expenditures | −$95.6M | −$104.4M | −$66.9M | −$47.1M | −$48.1M | −$63.9M | −$134.5M | −$77.7M | −$43.5M | −$47.3M |
| Investments (net) | −$12.4M | −$390.8M | −$94.2M | $4.9M | $76,000 | −$7.8M | $2.3M | $910,000 | $17.4M | −$42.6M |
| Acquisitions & other investing | $0 | $104.4M | $66.9M | −$16.4M | −$113.4M | $3.7M | −$30.5M | $27.1M | −$1.20B | $47.3M |
| Cash from investing activities | −$108.1M | −$390.8M | −$94.2M | −$58.6M | −$161.4M | −$68.1M | −$162.7M | −$49.7M | −$1.22B | −$42.6M |
| Financing activities | ||||||||||
| Dividends paid | — | — | −$93.2M | −$5.5M | −$2.0M | −$44.6M | −$434,000 | — | $0 | $0 |
| Share repurchases & issuance (net) | −$221,000 | −$52.5M | −$275.0M | −$125.0M | −$4.8M | −$100.0M | −$6.5M | −$7.8M | −$7.1M | −$4.9M |
| Net borrowing (repayment) | $50.8M | $299.4M | $54.5M | −$107.8M | −$100.2M | $281.2M | −$9.2M | −$493.8M | $1.17B | −$20.7M |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $349.6M | $0 | $0 |
| Other financing | −$22.3M | −$9.0M | $83.8M | −$13.7M | $8.8M | −$15.0M | $7.4M | −$28.8M | $5.1M | $10.5M |
| Cash from financing activities | $28.3M | $237.9M | −$229.9M | −$252.0M | −$98.2M | $121.6M | −$8.8M | −$180.9M | $1.17B | −$15.1M |
| Summary | ||||||||||
| Net change in cash | −$11.3M | −$30.0M | −$180.3M | −$56.8M | $43.3M | $271.3M | $60.1M | −$36.1M | $72.9M | $53.9M |
| Cash at end of period | $235.0M | $246.4M | $276.4M | $456.7M | $513.4M | $470.2M | $198.9M | $138.8M | $174.9M | $102.1M |
| Free cash flow | −$45.3M | $25.0M | $73.1M | $217.4M | $264.3M | $139.9M | $96.9M | $121.9M | $71.0M | $69.1M |
| Free cash flow margin | −2.8% | 1.6% | 4.7% | 14.0% | 17.1% | 10.2% | 6.4% | 8.3% | 6.0% | 7.0% |
| Capex / revenue | 5.8% | 6.5% | 4.3% | 3.0% | 3.1% | 4.7% | 8.9% | 5.3% | 3.7% | 4.8% |
| Operating cash flow / net income | — | — | 2.07 | 1.46 | 1.85 | 1.52 | 4.61 | 3.28 | 1.77 | 1.56 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | $4.6M | −$4.6M | −$1.7M | −$5.4M | −$484.1M | −$25.3M | $19.4M | −$10.7M | −$12.4M | −$3.3M | $19.8M | $19.5M |
| Depreciation & amortization | $38.1M | $38.4M | $38.4M | $38.5M | $37.7M | $37.2M | $37.6M | $36.0M | $36.8M | $30.6M | $31.0M | $30.6M |
| Stock-based compensation | −$5.2M | $5.2M | $5.8M | $5.6M | $5.3M | $1.9M | $7.2M | $4.4M | $7.2M | $5.6M | $5.8M | $5.5M |
| Change in working capital | $30.6M | −$30.6M | −$15.3M | $24.3M | −$18.0M | −$24.7M | −$12.0M | $22.4M | $938,000 | −$23.4M | $10.1M | −$34.1M |
| Other non-cash items | −$45.4M | $1.4M | −$15.4M | −$22.1M | $468.0M | −$368,000 | −$1.4M | −$29.6M | $7.8M | $6.2M | −$8.0M | $5.3M |
| Cash from operating activities | $22.8M | $9.8M | $11.8M | $40.9M | $8.9M | −$11.3M | $50.7M | $22.5M | $40.4M | $15.8M | $58.8M | $26.8M |
| Investing activities | ||||||||||||
| Capital expenditures | −$14.8M | −$14.8M | −$31.4M | −$15.2M | −$20.1M | −$28.9M | −$39.6M | −$29.6M | −$29.7M | −$15.5M | −$24.5M | −$13.1M |
| Investments (net) | −$31.0M | $0 | −$3.5M | −$15.6M | −$21.6M | −$35.9M | −$4.2M | −$10.4M | −$322.2M | −$54.0M | −$57.2M | −$7.7M |
| Acquisitions & other investing | $2.5M | $0 | $0 | $15.2M | $20.1M | $28.9M | $39.6M | $29.6M | $29.7M | $15.5M | $24.5M | $13.1M |
| Cash from investing activities | −$43.3M | −$14.8M | −$34.9M | −$15.6M | −$21.6M | −$35.9M | −$4.2M | −$10.4M | −$322.2M | −$54.0M | −$57.2M | −$7.7M |
| Financing activities | ||||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | −$655,000 |
| Share repurchases & issuance (net) | — | — | −$137,000 | −$199,000 | −$221,000 | — | −$2.5M | −$171,000 | −$50.0M | −$3.1M | −$314,000 | −$125.0M |
| Net borrowing (repayment) | $6.5M | $8.9M | $24.6M | −$10.0M | −$3.0M | $39.2M | −$4.5M | −$19.7M | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | −$8.1M | −$615,000 | −$134,000 | −$75,000 | −$17.9M | −$3.8M | −$136,000 | $0 | −$43.7M | $361.8M | −$6.6M | $76.0M |
| Cash from financing activities | −$1.6M | $8.3M | $24.3M | −$10.2M | −$21.1M | $35.4M | −$7.2M | −$19.9M | −$93.7M | $358.7M | −$6.9M | −$49.7M |
| Summary | ||||||||||||
| Net change in cash | −$23.2M | $1.8M | $2.9M | $14.3M | −$21.2M | −$7.3M | $31.2M | −$79,000 | −$376.7M | $315.5M | $2.7M | −$35.5M |
| Cash at end of period | $213.7M | $236.8M | $235.0M | $232.2M | $217.9M | $239.1M | $246.4M | $215.2M | $215.2M | $591.9M | $276.4M | $273.7M |
| Free cash flow | $37.6M | −$5.0M | −$19.6M | $25.8M | −$11.2M | −$40.2M | $11.2M | −$7.2M | $10.7M | $291,000 | $34.2M | $13.7M |
| Free cash flow margin | 9.0% | −1.3% | −4.5% | 6.4% | −2.7% | −10.5% | 2.5% | −1.9% | 2.6% | 0.1% | 8.6% | 3.6% |
| Capex / revenue | 3.5% | 3.8% | 7.2% | 3.8% | 4.8% | 7.6% | 8.9% | 7.8% | 7.1% | 4.2% | 6.2% | 3.4% |
| Operating cash flow / net income | 4.94 | — | — | — | — | — | 2.61 | — | — | — | 2.96 | 1.37 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
IART cash generation
In fiscal 2025 (ended December 31, 2025), Integra LifeSciences generated $50.4 million of cash from operations (down 61.1%) and spent $95.6 million on capital expenditures, leaving free cash flow of -$45.3 million, −2.8% of revenue. It returned $0.2 million to shareholders through dividends ($0) and net share buybacks ($0.2 million). Cash and equivalents fell by $11.3 million over the year.
Related: IART income statement, IART balance sheet. See the IART stock overview for the latest quote and news.
IART cash flow FAQ
What is Integra LifeSciences's free cash flow?
Integra LifeSciences's free cash flow was -$45.3 million in fiscal 2025: $50.4 million of operating cash flow minus $95.6 million of capital expenditures It was $25.0 million a year earlier..
How much cash does Integra LifeSciences generate from operations?
Integra LifeSciences generated $50.4 million of cash from operating activities in fiscal 2025.
How much does Integra LifeSciences spend on capital expenditures?
Integra LifeSciences spent $95.6 million on capital expenditures in fiscal 2025, 5.8% of revenue, compared with $104.4 million the year before.
How much stock does Integra LifeSciences buy back?
Integra LifeSciences spent $0.2 million on net share repurchases in fiscal 2025.